SignalMacro

AN AMAZING BREAKTHROUGH BY $RVMD THAT SHOULD SEE THE NAME RALLY NOT JUST ON PANCREATIC CANCER TAM BUT ON THE “COPY PASTE” POTENTIAL FOR THEM TO USE RAS BEING A DRUGGABLE TARGET FOR FURTHER THINGS BEYO

RVMD

$210.02

-0.40%

What changed

WE DETAILED THIS DYNAMIC IN OUR 26 TRADES FOR 2026. HTTPS://T.CO/UVL3UVMC0G — VIA @CITRINI

Why it matters

Breakthrough RAS platform expands TAM beyond pancreatic cancer, amplifying catalyst potential.

Sources